M tal animal models aimed at the efficient introduction of exogenous genes into hematopoietic stem cells using retroviral vectors.'"l The ability of pluripotential stem cells to repopulate all hematopoietic cell lineages, and their capacity for ~elf-renewal'~~ make them attractive target cells to correct genetic defects affecting hematopoietic c e k 6 However, this has proven somewhat difficult technically, primarily because whole bone marrow contains very few pluripotential stem cells and, as yet, no unique cell surface markers have been identified on these cells making it difficult to purify sufficient quantities for detailed analysis. Thus, gene transfer into these cells has been inefficient7,* and even when transfer has been achieved, appropriate expression of the transferred gene has often been problematic, possibly because pluripotential stem cells undergo many differentiation steps before reaching maturity, which might interfere with the proper expression of the introduced gene. Therefore, it has been suggested that, for certain diseases that effect the lymphoid compartment or which might be treated by augmenting immune responses, gene transfer into primary lymphocytes might be helpful and in some cases Primary lymphocytes are easy to obtain; many of them are long-lived; and they can be easily induced to proliferate, a required step for infection using retroviral vectors." Such advantages have thus recently motivated research on gene transfer into primary lymphocytes.
In this report, we describe efficient retroviral vector-mediated gene transfer (approximately 1 to 5 copies per genome) of the human adenosine deaminase (ADA) gene and the bacterial neomycin phosphotransferase I1 (neo) gene into mature, murine lymph node T and B lymphocytes and immature, double negative (DN) thymocytes that contain precursor cells capable of reconstituting the entire T-cell lineage.12 Efficient gene transfer and expression were achieved without drug selection, which is commonly used to enrich for infected cells. The human ADA protein was expressed in the mature T and B lymphocytes at levels comparable to the endogenous murine ADA isoenzyme. Expression was somewhat lower in the DN thymocytes, but was still readily detectable. The infection protocol described here can be completed within 24 hours, hence, it should be useful for in vivo animal reconstitution studies.
MATERIALS AND METHODS
Mice. Balb/cBy male and female mice were purchased from the Jackson Laboratory, Bar Harbor, ME. Plasmids. pN2I3 was a generous gift from E. Gilboa. pN2 and pAsADA are Moloney murine leukemia virus (MoMLV)-based retroviral vectors that contain the neo gene, which is expressed from the MLV long terminal repeat (LTR) promoter. pAsADA contains the human ADA gene, which is expressed from its endogenous promoter. This vector was kindly provided by Gene Therapy, Inc (Gaithersburg, MD).
The GP+E-86 cell line is a National Institutes of Health (NIH) 3T3-based, ecotropic murine packaging cell line.I4 GP+E-86 cells were transfected with 5 pg of vector plasmid DNA using the polybrene/dimethyl sulfoxide (DMSO) shock method,15 followed by selection with (3418 (0.35 mg/mL) and GPT (xanthine 0.25 mg/mL, mycophenolic acid 25 pg/mL, and hypoxanthine 15 pg/mL). N2-transfected GP+E-86 cells yielded virus stocks of 2.0 X lo7 colony-forming units (CFU) per milliliter, quantitated by inoculation of NIH 3T3 cells with serial dilutions of helper cell supernatant, followed by selection in the presence of G418 (0.35 mg/mL) for 2 weeks at which time colonies were counted. AsADA-transfected cells yielded virus stocks of 1.5 X io' CW/mL.
Preparation of DN thymocytes. Thymocytes from 3-to 5-weekold mice were treated with a cocktail of the monoclonal antibodies (MoAbs) GK1.5 (rat anti-mouse CD4),I6,l7 3.168 (rat antimouse CD8)," and a mixture of guinea pig and rabbit complement to remove CD4' and CD8' cells. This protocol routinely yields a DN cell population that contains less than 2% CD4' and less than 0.5% CD8+ cells as analyzed by flow cytometry. DN cells are then cul-846 KUO ET AL tured in RPMI media supplemented with gentamicin (50 pg/mL) (GIBCO, Grand Island, NY), 2-mercaptoethanol (50 pmol/L) (Sigma, St Louis, MO), and stimulated with recombinant human interleukin-7 (rIL-7,50 ng/mL) (PeproTech, Rocky Hill, NJ) for 24 hours before infection.
Preparation of peripheral lymph node lymphocytes. Lymph nodes (LN) were obtained from adult mice. T lymphocytes were isolated by treatment of LN cell suspensions with the MoAb J 1 Id, a rat antimurine heat stable antigen (HSA) antibody that removes practically all B cells from LNL9 with the addition ofcomplement. B lymphocytes were isolated by treatment of LN cell suspensions with the MoAb Jlj, a rat antimouse Thy-1.2 antibody," and complement. These procedures routinely yield enriched T and B cell populations that contain greater than 97% T or B cells, respectively, as analyzed by flow cytometry. Fewer than 0.5% of B cells were detected in T-cell-enriched populations and, similarly, fewer than 0.5% of T cells were detected in B-cell-enriched populations (data not shown). T cells were then cultured in RPMI media supplemented with gentamicin (50 pg/mL), 2-mercaptoethanoI(50 &mol/ L), and stimulated with concanavalin A (ConA) (4 pg/mL). After 24 hours, the cells were washed twice and resuspended in medium containing 10 ng/mL of recombinant murine IL-2 (PeproTech). B cells were stimulated with lipopolysaccharide (50 pg/mL).
Virus infections. Gene transfer into primary lymphoid cells was attempted by cocultivation with virus-producingcells, and by inoculation with supernatant from virus-producing cells. Infection by cocultivation was carried out by plating IO X IO6 stimulated lymphoid targets at a density of 1 X IO6 cells/mL RPMI media, onto a confluent lawn of irradiated (1,600 rads) virus-producing cells in 100 mm tissue culture plates. Polybrene (6 pg/mL) and rIL-7 (50 ng/mL) for DN thymocytes, rIL-2 (10 ng/mL) for T lymphocytes, or lipopolysaccharide (50 pg/mL) for B lymphocytes was added to the media. Twenty-four hours later, primary target cells were harvested and cultured in fresh media containing stimulatory lymphokines/mitogens. Seventy-two hours later, target cell genomic DNA was extracted for Southern blotting analysis, and protein extracts were made for assaying for ADA activity. Infection by inoculation was carried out by incubating 20 X IO6 DN thymocytes in 5.0 mL of virus supernatant in the presence of rIL-7 (50 ng/mL) and polybrene (8 pg/mL) for 2 hours at 37°C. Cells were centrifuged, resuspended in fresh media plus rIL-7 (50 ng/mL), and cultivated in tissue culture plates until harvesting. To ensure that the vector viral supernatants used to inoculate primary lymphocytes contained infectious vector virions, we typically infected NIH 3T3 cells in parallel to ensure that infectious vector virus was contained in the supernatant, and always observed infection of NIH 3T3 cells.
DNA isolation and Southern blot analysis. Southern blotting with 10 &lane of Sac I-digested genomic DNA was performed according to standard methods:' using a "P-labeled neo-specific probe, the 1.3 Kb EcoRI-Xho I fragment from pN2. The probe was labeled by random priming. Controls for copy number were made by digesting pN2 and pAsADA with Sac I, and loading amounts corresponding to 1 and 10 proviral copies/genome on the gel.
ADA assay. Target cells, I X IO6, were lysed 2 days postinfection by freeze/thaw method, and the lysate was applied to a cellulose acetate plate (Helena Laboratories, Beaumont, TX). Human and murine ADA isoenzymes were separated by electrophoresis on cellulose acetate plates! Enzyme activity was detected by reaction of the separated ADA isoenzymes on the plate with an agar overlay containing adenosine (2 mg/mL) (Sigma), nucleoside phosphorylase (15 pg/mL) (Boehringer Mannheim, Indianapolis, IN), xanthine oxidase (0.06 U/mL) (Boehringer Mannheim), phenazine methosulfate (0.0 I mg/mL) (Sigma), and dimethylthiazol diphenyltetrazolium bromide (0.1 mg/mL) (Sigma) in phosphate buffer at 37°C for 20 minutes in the dark.
RESULTS
Eficient gene tranger into DN thymocytes. CD4-CD8-DN thymocytes were derived from 3-to 5-week-old mice, by incubation of thymocytes with anti-CD4 and anti-CD8 MoAbs in the presence of complement. For these studies, the vectors N2 and AsADA were used. Both N2 and AsADA are MoMLV-based vectors. The ecotropic packaging cell line, GP+E-S6,l4 was used to produce virus. These cells have been designed to produce MoMLV-based vector virus in the absence of replication-competent MLV. N2 contains the neo gene and AsADA contains both the neo and human ADA genes (Fig 1) . DN thymocytes were infected by cocultivation with irradiated, confluent cultures of either N2-or AsADA-vector virus-producing cells or by inoculation with virus-containing supernatants in the presence of ~3L-7.~' rIL-7 is required to stimulate the DN thymocytes to proliferate, a requisite step for infection by MoMLV-based vector virus." Twentyfour hours after cocultivation, target cells were transferred to new plates and cultured for 2 days to allow any lifted producer cells to readhere. This incubation period also allows the cells time to express the transferred gene. Cells were then analyzed for integration ofviral DNA by Southern blot analysis, and for the presence of the human ADA protein by enzymatic assay.
Genomic DNA was digested with Sac I. Successful provirus formation should yield a 3.3 kb band in N2-infected cells, and a 3.7 kb band in AsADA-infected cells after hybridization with a 1.3 kb neo-specific sequence (Fig 1) . As shown in Fig 2, a signal equivalent to approximately 1 to 5 proviruses per cell (quantitated by scanning gel densitometry and compared with plasmid controls equivalent to 1 or 10 copies) was obtained after cocultivation of DN thymocytes with irradiated N2 producer cells (Fig 2A, lane 7) or AsADA producer cells (Fig 2B, lane 7) . In contrast, the cells infected by inoculation yielded very weak signals, N2-inoculated (Fig 2A, lane 6) and AsADA-inoculated (Fig 2B, lane  6 ), which were only detectable after a 2-week exposure (data For personal use only. on January 1, 2018. by guest www.bloodjournal.org From It should be noted that we attempted to infect primary lymphocytes by inoculation with longer incubation periods including 6 hours and overnight. Moreover, we also attempted to do this with concentrated viral preparations in which the viral titers were increased approximately eightfold (1 X lo8 titer per mL on NIH 3T3 cells). Even with concentrated virus stocks and longer incubation periods, we were not able to obtain as efficient gene transfer as with cocultivation. Uninfected, control lymphocytes (Fig 2A and  B , lanes 5) and GP+E-86 cells (Fig 2A and B, lanes 3) were negative for neo. N2-producer cells (Fig 2A, lane 4) and AsADA-producer cells (Fig 2B, lane 4) served as positive controls.
Although thymocytes infected by cocultivation were added to fresh tissue culture plates to allow any producer cells that might have lifted during the cocultivation procedure to readhere, we believe that it was still useful to control for helper cells that might be contaminating our primary cell cultures even after this step. To control for this, we assayed supernatants from irradiated AsADA-and N2-helper cells cultured without lymphocytes. They were subjected to the same manipulations as cultures cocultivated with lymphocytes. These supernatants were then added to freshly obtained DN thymocytes followed immediately by extraction of genomic DNA (an aliquot of the AsADA supernatant mixture was saved for later use in the ADA assay). DN thymocytes were added to act as camer cells because the number of lifted cells might have been relatively small. As can be seen in Fig 2 (A and B, lanes 8 ) no signals were obtained from this control, indicating that the positive signals from infected double negative thymocytes (Fig 2A and  B, lanes 7) were not caused by contaminating helper cells.
Expression ofthe human ADA gene in murine DN thymocyles. DN 
in the previous section, were harvested, transferred to new plates, and incubated for 2 days to allow sufficient expression of the human ADA gene, and in the case of the cocultivated target cells, to also allow any lifted helper cells to readhere. The target DN thymocytes were then assayed for human ADA protein expression. Figure 2C shows an ADA assay of the target DN thymocytes. The human ADA protein was separated from the murine ADA isoenzyme by electrophoresis of target cell lysate on cellulose acetate plates. Detection of the protein is by colorimetric enzyme assay (Materials and Methods). The results show that the exogenous human ADA gene was expressed in the cocultivated thymocytes. The level of expression was somewhat lower than expression of the endogenous murine ADA gene (Fig 2C, lane 3) . No expression of human ADA was seen in the DN thymocytes inoculated with free AsADA-vector virus stocks (Fig 2C, lane 2) . This result is in concurrence with the extremely low provirus copy number obtained by inoculation of DN thymocytes (Fig 2B, lane 6 ). Murine DN thymocytes and human H-9 cells (T-cell line) were used as standards for the murine and human isoenzymes (Fig 2C,  lanes I and 5, respectively) . Fig 2C, lane 4 represents a "lifting" control, using supernatant from irradiated AsADAhelper cells that were not cocultivated with thymocytes, mixed with freshly obtained DN thymocytes immediately before ADA assay. Human ADA expression was not detected, indicating that the ADA signal obtained from the cocultivated DN thymocytes is not attributable to helper cell contamination.
Eficient transfer and expression of the human ADA gene in murine lymph node T and B lymphocytes. Lymph node T and B cells were prepared as described in Materials and Methods. Cells were stimulated for 24 hours with either ConA for T cells or lipopolysaccharide (LPS) for B cells, then washed and cocultivated on a confluent irradiated lawn of AsADA-producer cells in the presence of polybrene, and rIL-2 (T cells) or LPS (B cells). After 24 hours, the target cells were transferred to fresh plates and cultured for 48 hours to allow any lifted helper cells to readhere. Cells were then harvested and genomic DNA was extracted, or aliquots were taken for ADA assay of protein expression.
Southern blotting of target cell DNA showed that an average of approximately one vector provirus per cell could be transferred to both T and B lymphocytes (Figs 3A and 4A, lanes 6) when compared with plasmid copy number controls equivalent to I and 10 copies per cell ( Figs 3A and 4A,  lanes 1 and 2, respectively) . A lifting control, performed by mixing the supernatant from irradiated plates of helper cells that were not cocultivated with target cells with freshly obtained lymph node cells immediately before DNA extraction or ADA assay, yielded no signal ( Figs 3A and 4A, lanes  7) . Again, this indicates that the signals obtained from the cocultivated target cells did not result from contamination from lifted helper cells.
ADA assay of target cell lysates showed that both lymph node T and B lymphocytes cocultivated with AsADA-producer cells expressed the exogenous human ADA protein at levels comparable to the endogenous murine isoenzyme ( Fig 3B, lane 2; Fig 4B, lane 4) . The lifting control, as described previously, for contaminating helper cells, did not yield an ADA signal ( Fig 3B, lane 1; Fig 4B, lane 5) . These results suggest that the efficiency of infection is high, approximately one copy per cell, and the level of expression of the exogenous ADA gene is comparable to the level of expression of the endogenous gene.
DISCUSSION
The object of this work was to test if efficient gene transfer and expression in primary lymphocytes could be obtained without the need for drug selection to enrich for infected cells. The ability to introduce a gene into primary lymphocytes during a relatively short period oftime in vitro is particularly important because it minimizes cell damage and cell surface alterations that usually result in inappropriate homing in vivo. There have been previous reports of retroviralmediated gene transfer into T cells. However, these reports have been mostly limited to transformed T-cell lines,22 longterm T-cell clone^,^^'^ or tumor infiltrating lymphocytes (TIL) obtained after long-term expansion in the presence of IL-2,9 and, in the majority of instances, drug selection was required to enrich for the infected population. The one report depicting gene transfer into primary T cells within a few days after explantation described on average gene transfer into only 5% of the primary T cells, and this was only determined for the cytotoxic T-lymphocyte subpopula ti or^.^^ Thus, besides describing for the first time efficient gene transfer into primary B cells and DN thymocytes, this is the first report delineating efficient gene transfer into primary mature T cells that have not been expanded for long periods in vitro.
The data described in this report show that gene transfer approached on average 1 to 5 proviruses per cell and that the level of expression of the exogenous ADA gene was comparable to that of the endogenous ADA gene in the target cell population. Although we cannot be sure from the experiments described that every cell has been targeted, it seems likely that a large percentage of the cells have been infected. If, for example, only 1 % of the cells were effectively infected, they would harbor 100 to 500 proviruses per cell, which would result in a heavy mutational burden and in all likelihood have deleterious effects on their normal functioning and survival. Homing experiments using SCID mice as recipients indicated that the infected cells retain their ability to home properly and that expression of the human ADA gene could be detected for at least 3 months in these animals posttransfer (manuscript in preparation). Thus, it seems unlikely that only a small percentage of the cells have been targeted. However, to more accurately assess the proportion of infected cells, vectors encoding histochemically detectable proteins (such as ,&galactosidase and the human placental alkaline ph~sphatase)'~ are being constructed for future studies.
There were a few parameters that seem to be important for efficient gene transfer into primary murine lymphocytes ( I ) The producer cell lines needed to produce virus stocks yielding a titer of about IO7 CFU/mL on NIH 3T3 cells. It should be noted that we examined gene transfer into pri- virus-producing cells, as shown for other protocols?26 was much more efficient than infection with free virus stocks. We also tested supernatant inoculation versus cocultivation for transfer into mature T and B cells. As with DN thymocytes, supernatant inoculation was not nearly as efficient as cocultivation for efficient gene transfer (data not shown). (3) As expected, the presence or the absence of the appropriate mitogen and/or growth factor is important for efficient gene transfer because the retroviral vectors used are derived from the MoMLV oncoretrovirus, which requires cellular replication for provirus formation."
With the AsADA vector we have obtained good expression of the introduced human ADA gene in the primary cell targets, comparable to the expression levels of the endogenous ADA gene. However, we were not able to obtain similar levels of expression with other vectors. We have used a number of different murine leukemia virus-based vectors utilizing various promoters, with inconsistent expression results in primary cells (even though consistently good efficiency of transfer was obtained with all vectors used employing the cocultivation protocol). The other promoters human mouse that we used include the herpes simplex virus tk promoter, the SV40 early gene promoter, and the cytomegalovirus immediate early gene promoter. However, it should be noted that these promoters might yield acceptable levels ofexpression in primary lymphocytes in a different vector context. We have found that almost all of the vectors express well in various established cell lines, such as NIH 3T3 and BW5417. However, the ability of the vector to express in immortalized or tumor cell lines was a poor indication of its ability to express in primary lymphocytes. We are currently testing a variety of vectors with different expression signals in search of reliable expression for any exogenous gene we wish to transfer into primary lymphocytes.
There are a number of diseases that might be amenable to treatment by gene transfer into primary lymphocytes. Already, primary human lymphocytes from patients with severe combined immunodeficiency (SCID) caused by a defect in the ADA gene, have been used as recipients for retroviral-mediated transfer of the normal human ADA gene.IO One important factor for selecting SCID disease for the first treatment using somatic cell gene therapy was that transfer of the normal ADA gene would confer a selective growth advantage to the patient's lymphocytes that were successfully infected and expressed the exogenous ADA gene. Consequently, one could expect to obtain therapeutic benefit without the need for very efficient gene transfer approaching one exogenous gene per cell. However, more efficient gene transfer into primary B and T cells could enhance treatment even of this disease. We feel that our experiments showing efficient gene transfer into primary LN B and T cells are a relevant model for efficient gene transfer into peripheral blood lymphocytes because lymph nodes and peripheral blood contain very similar ratios of T and B cell subsets. The reason we used LN T and B cells is that it is much easier to obtain the numbers of cells required to perform the experiments described from the lymph nodes of mice instead of from their peripheral blood.
For other diseases, the importance of efficiently introducing exogenous genes into primary lymphocytes is more cru- Adoptive i m m u n~t h e r a p y~*~~ is another procedure that can benefit from efficient gene transfer into primary lymphocytes. Recently, a number of procedures have been proposed that involve the in vitro expansion of autologous T cells for transplantation into patients to assist in combating cancer,35 infections in immunocompromised hosts,36 and AIDS.37 Genetic manipulation of these cells might offer added advantages in providing more potent responses and additional levels of safety. The types of genes that are potentially useful for this purpose include those encoding immunoregulatory molecules capable of augmenting immune responses, or growth stimulators that can induce autocrine expansion of the lymphocytes after reintroduction into a patient. This could eliminate the need for long-term cell expansion in vitro, which is currently required to accumulate enough cells of therapeutic bet~efit.~~.~' Also of potential importance is the efficient introduction of "suicide" genes3' that can be used to destroy the transplanted cells if they become tumorigenic, develop any other abnormalities, or are no longer necessary.
In addition to its predicted value for somatic cell gene therapy, genetic manipulation of primary lymphocytes might prove useful for studying basic questions in lymphocyte biology. For example, efficient transfer of immunoregulatory genes into immature DN thymocytes and other lymphocyte precursors is potentially important for studies of T-cell development. Also, gene marking of progenitor lymphoid cells with retroviral vectors offers a tool for the study of lymphocyte differentiation and homing.
In summary, it was shown that retroviral vectors can be used to efficiently introduce exogenous genes into primary murine lymphocytes on an average of one to five copies per cell without the need for drug selection to enrich for stably infected cells. Moreover, we show that the transferred human ADA gene is expressed at high levels in these cells, 
